These two invite comparison because they share a manufacturer and arrived in the public conversation as the injection and the pill from the same company. That framing suggests one is simply a more convenient version of the other. It is not. They are different molecules doing overlapping but distinct things, and the gap in their trial results is large enough that convenience alone should not settle the choice.
What each one is
Mounjaro is the brand name for tirzepatide, a peptide given as a once-weekly injection using a pen, stored in the fridge. Orforglipron is a small-molecule tablet taken once daily at any time of day, stored at room temperature. Mounjaro has been available in the UK for some time and is used both privately and, through specialist services, on the NHS. Orforglipron was authorised on 10 August 2026 and has not yet launched here, so it cannot currently be prescribed.
The mechanism difference that explains the results
Orforglipron activates the GLP-1 receptor, reducing appetite, slowing stomach emptying and supporting blood sugar control. Tirzepatide activates the GLP-1 receptor too, and additionally a second one called GIP. That dual action is widely thought to be part of why tirzepatide produces greater weight loss than GLP-1 medicines acting alone. This is not a marketing distinction. It is the most plausible explanation for a consistent and substantial difference in outcomes across trials.
The numbers
In its main obesity trial, tirzepatide at its highest dose produced average weight loss of around 21% of body weight over 72 weeks. In ATTAIN-1, orforglipron at its highest dose produced around 11% over the same 72 weeks, against roughly 2% on placebo. Both are clinically meaningful; a 10% reduction is the point at which blood pressure, blood sugar, joint pain and sleep apnoea reliably improve. But roughly twice the average weight loss is a large difference, and it is the single most important fact in this comparison. Anyone told that orforglipron is the tablet version of Mounjaro has been misinformed.
Where orforglipron genuinely wins
Convenience, and not trivially. There is no injection, which matters enormously to people with a needle phobia and to a wider group who simply will not commit to injecting themselves weekly. There is no refrigeration, so no cool bag, no planning around holidays, and none of the anxiety about a pen left out overnight. There is no sharps bin and no disposal problem. And unlike the other tablet in this category, there is no empty-stomach routine and no waiting before breakfast. For someone who would otherwise not take any treatment at all, an 11% average that they will actually follow is worth more than a 21% average that they will not.
Side effects and tolerability
Both share the class profile: nausea, constipation, diarrhoea, vomiting and indigestion, clustered around starting and each dose increase, mostly settling with time. Neither is obviously gentler. The rhythm differs, in that a weekly injection concentrates the dose and some people notice a pattern across the week, where a daily tablet spreads it evenly. Both escalate over months, both carry the same uncommon risks around pancreatitis and gallbladder problems, and both need the same honest medical history at assessment.
Dose schedules
Mounjaro moves through six strengths from 2.5 mg to 15 mg, injected weekly, with at least four weeks at each step. Orforglipron moves through six daily doses from 0.8 mg to 17.2 mg, with at least 30 days at each step. The milligram figures are not comparable between the two, since they are entirely different molecules, and reading 17.2 as stronger than 15 would be a mistake. Both take roughly five months to reach the top of the range if every step is taken at the minimum interval, and neither obliges anyone to get there.
Type 2 diabetes
Both are authorised for blood sugar control in type 2 diabetes as well as for weight management, which matters because the two conditions travel together so often. Tirzepatide's dual action gives it a strong record on blood sugar, and orforglipron was authorised for insufficiently controlled type 2 diabetes on its own evidence, including a trial that compared it favourably with oral semaglutide in that population. For someone managing both weight and blood sugar, the choice therefore involves a prescriber weighing HbA1c targets, existing diabetes medicines and the risk of blood sugar dropping too low if insulin or a sulfonylurea is already in use, alongside the weight-loss figures. It is a more layered decision than the obesity comparison alone.
Who was actually studied
Trial populations shape what the averages mean. ATTAIN-1 enrolled adults with obesity or overweight without type 2 diabetes, and ATTAIN-2 those who also had it, with the second group losing slightly less, which is the usual pattern because weight loss tends to be harder alongside diabetes. Tirzepatide's headline figure likewise comes from a trial in people without diabetes. Comparing a figure from one population against a figure from another is a common error in this area and inflates or deflates differences depending on which pairing is chosen. The broad ordering survives the caveat, but it is worth knowing that the numbers are not drawn from the same room of people.
Which one, for whom
If the priority is the largest likely weight loss and injecting is acceptable, the evidence points clearly to tirzepatide, and it has the further advantage of being available now. If injections are the barrier, whether through phobia, dexterity, storage or simple aversion, orforglipron becomes the more realistic option once it launches, at the cost of a lower expected result. There is also a middle path worth raising at review: reaching a target on an injectable and then moving to a tablet for maintenance, an approach with early trial evidence behind it. What does not make sense is switching away from a Mounjaro course that is working well in order to try something newer with more modest published results.
